Looks like you’re on the US site. Choose another location to see content specific to your location

Home Pharmaceutical Takeda Launches Orzeyful Orexin Agonist for US Narcolepsy
NEWS & BLOGS IMAGES (79)

Takeda Launches Orzeyful Orexin Agonist for US Narcolepsy

17th November 2026

Takeda has launched Orzeyful (oveporexton), its oral orexin receptor 2 (OX2R) agonist for narcolepsy type 1, in the US market via Accredo Specialty Pharmacy distribution. Announced on 13 November 2026, the commercial launch follows August 2026 FDA approval (with Schedule IV classification) and marks a substantial category-defining milestone for Takeda’s orexin franchise strategy, opening a new therapeutic pathway in a long-underserved rare neurological disorder.


Orzeyful is approved for adults with narcolepsy type 1, a rare chronic neurological disorder caused by loss of orexin-producing neurons that drives fragmented night-time sleep, excessive daytime sleepiness, cognitive difficulties and cataplexy (sudden temporary muscle tone loss). The orally administered OX2R agonist selectively activates OX2R pathways to restore signalling, promoting daytime wakefulness and reducing abnormal REM sleep phenomena. The most frequently reported adverse events in clinical evaluations were insomnia, excessive saliva production and increased urinary urgency and frequency. In addition to US approval, the drug is also approved in China and Japan for adult narcolepsy type 1. Accredo Specialty Pharmacy, a division of Evernorth Health Services, handles US distribution, with licensed healthcare practitioners eligible to prescribe. Takeda offers patient support programmes to help eligible adults navigate treatment initiation and coverage.

Rhonda Pacheco, President of Takeda’s US business unit, positioned the launch as a meaningful milestone and highlighted continued focus on care and access support. Orzeyful is the lead asset in Takeda’s orexin pipeline, with TAK-360 in development for idiopathic hypersomnia, narcolepsy type 1 and narcolepsy type 2, and TAK-495 also advancing through the pipeline. Takeda is additionally developing digital tools and biomarker diagnostics to identify narcolepsy type 1 earlier, extending the commercial opportunity across the full patient journey. The commercial case rests on substantial unmet need: current narcolepsy standard of care has been dominated by oxybate-based therapies and stimulant medications, with orexin pathway targeting representing a mechanistically differentiated first-in-class approach that addresses the underlying biology of narcolepsy type 1. Dosing, clinical trial efficacy data and pricing were not disclosed in the launch announcement.


The commercial signal is a category-defining launch in narcolepsy type 1 therapeutics, with orexin agonist mechanism offering mechanistically differentiated positioning against established oxybate and stimulant workflows. Takeda’s broader orexin pipeline extends the long-term franchise opportunity across related sleep disorders. Expect sustained commercial momentum across orexin-based sleep disorder therapeutics and continued focus on narcolepsy diagnostic infrastructure through 2027 and 2028.

For the latest updates and in-depth insights into the world of Pharmaceutical, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today! 

Stay informed

Receive the latest industry news, Tips and straight to your inbox.

wpChatIcon
wpChatIcon